• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Analyst Comment

Aiforia raised almost 10 MEUR in a directed issue

Aiforia Technologies

Translation: Original comment published in Finnish on 05/23/2024 at 9:18 am EEST

The issue was fully expected, as we believe the company’s implementation of its growth strategy requires additional funding to be collected this year. The terms (EUR 3.5 per share, gross proceeds of some 10 MEUR) were quite well in line with our expectations. With the issue, the company can continue implementing its growth strategy that has progressed well without material short-term financing risks.

9.95 MEUR collected in the issue before costs

In the directed share issue announced yesterday, Aiforia will issue 2.84 million new shares. The subscription price of the shares in the issue was EUR 3.50 per share, which corresponds to a discount of some 11.4% on yesterday’s (5/22) closing price of EUR 3.95 per share. The issue was carried out in an accelerated bookbuilding process based on bids. The issue was aimed at domestic and international institutional investors and other professional investors. The new shares account for approximately 9.9% of all Aiforia shares after the issue, so the dilution is quite moderate.

The successful issue came as no surprise, as the implementation of Aiforia’s growth strategy has progressed well and we thus believe the company was in a good position in the financing negotiations. Aiforia raised gross proceeds of 9.95 MEUR in the share issue, which, after typical costs of around 5-10%, would correspond to net assets of good 9 MEUR. In our previous valuation (3/8/2024), we had included a 10 MEUR share issue in 2024 (and another one in 2025), at a price of EUR 3.10 per share, excluding costs. Considering the typical costs of approximately 5-10% for the directed issue carried out at EUR 3.5 per share, the issue was largely as expected.

Before the issue, we estimated that Aiforia will raise a total of some 20 MEUR in additional funding to enable maintaining growth investment and achieving cash-flow neutrality, so the directed issue covers around half of this. With our current forecasts, the company’s financing needs would be sufficient until the end of 2025 with the help of this issue, when the cash flow from operating activities (excl. investments) would be positive in the company’s objectives. With our forecasts, cash flow would be positive after investments in 2027, so any additional funding would presumably be raised with better visibility of the timing for achieving cash flow neutrality.

We feel the elimination of short-term financial uncertainties with expected terms is in principle positive for the company, even though a share issue carried out slightly below yesterday’s closing price may also bring short-term downward pressure to the share and room for play.

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Read more on company page

Key Estimate Figures2024-03-08

202324e25e
Revenue2.44.38.1
growth-%49.3 %80.1 %88.4 %
EBIT (adj.)-12.9-11.4-10.2
EBIT-% (adj.)-537.1 %-263.0 %-125.4 %
EPS (adj.)-0.50-0.44-0.39
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.neg.neg.
EV/EBITDAneg.neg.neg.

Forum discussions

In my opinion, the financing news was much better than I expected. I was certainly expecting a directed share issue, which would have been frustrating...
yesterday
by JusaVaan
23
nuways-ag.com NuWays Platform
yesterday
by Salvelinus
10
ecdp2026.org European Society of Digital and Integrative Pathology | ECDP2026 | 22nd... Today marks the start of a congress where Aiforia is...
yesterday
by Salvelinus
16
These types of bridge financing arrangements are quite common nowadays. It also indicates that the company genuinely believes cash flow positivity...
yesterday
24
Usually a company can and should raise debt only when the stock and cash flows are strong enough, this is kind of the opposite situation
6/16/2026, 1:53 PM
by Bullbear
1
Yeah, even if the loan eliminates the acute financing risk, we will likely see at least one more share issue. It is also possible that the potential...
6/16/2026, 9:49 AM
6
Below are the analyst’s comments. Referring to management’s previous statements, this is bridge financing instead of share issues for the period...
6/16/2026, 6:11 AM
by Opa
25